GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (NAS:KPTI) » Definitions » Shiller PE Ratio

KPTI (Karyopharm Therapeutics) Shiller PE Ratio : (As of Apr. 12, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Karyopharm Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Karyopharm Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Karyopharm Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karyopharm Therapeutics Shiller PE Ratio Chart

Karyopharm Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Karyopharm Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Karyopharm Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Karyopharm Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karyopharm Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Karyopharm Therapeutics's Shiller PE Ratio falls into.


;
;

Karyopharm Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Karyopharm Therapeutics's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Karyopharm Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-3.6/133.1571*133.1571
=-3.600

Current CPI (Dec. 2024) = 133.1571.

Karyopharm Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -11.100 99.621 -14.837
201506 -13.800 100.684 -18.251
201509 -12.750 100.392 -16.911
201512 -12.150 99.792 -16.212
201603 -11.250 100.470 -14.910
201606 -12.600 101.688 -16.499
201609 -10.350 101.861 -13.530
201612 -9.750 101.863 -12.745
201703 -10.650 102.862 -13.787
201706 -9.600 103.349 -12.369
201709 -9.750 104.136 -12.467
201712 -12.000 104.011 -15.363
201803 -11.700 105.290 -14.797
201806 -9.000 106.317 -11.272
201809 -11.850 106.507 -14.815
201812 -14.400 105.998 -18.090
201903 -16.350 107.251 -20.299
201906 -10.650 108.070 -13.122
201909 -10.050 108.329 -12.353
201912 -11.400 108.420 -14.001
202003 -11.700 108.902 -14.306
202006 -9.450 108.767 -11.569
202009 -10.950 109.815 -13.278
202012 -8.850 109.897 -10.723
202103 -11.550 111.754 -13.762
202106 -10.650 114.631 -12.371
202109 -10.350 115.734 -11.908
202112 6.900 117.630 7.811
202203 -7.950 121.301 -8.727
202206 -9.300 125.017 -9.906
202209 -6.750 125.227 -7.177
202212 -6.450 125.222 -6.859
202303 -4.500 127.348 -4.705
202306 -4.350 128.729 -4.500
202309 -4.500 129.860 -4.614
202312 -5.400 129.419 -5.556
202403 -4.800 131.776 -4.850
202406 -3.000 132.554 -3.014
202409 -3.900 133.029 -3.904
202412 -3.600 133.157 -3.600

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Karyopharm Therapeutics  (NAS:KPTI) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Karyopharm Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Karyopharm Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Karyopharm Therapeutics Business Description

Traded in Other Exchanges
Address
85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Executives
Stuart Poulton officer: EVP, Chief Development Officer 85 WELLS AVENUE, NEWTON MA 02459
Michael Mano officer: SVP, General Counsel&Secretary 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Sohanya Roshan Cheng officer: SVP Sales & Commercial Ops C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON MA 02459
Reshma Rangwala officer: EVP & Chief Medical Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Richard A. Paulson director, officer: President and CEO 85 WELLS AVENUE, NEWTON MA 02459
Michael Mason officer: EVP, CFO, Treasurer 300 3RD STREET, CAMBRIDGE MA 02142
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Garen G Bohlin director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Zhen Su director 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Stephen Mitchener officer: SVP, Chief Business Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Ran Frenkel officer: EVP, WW Development Operations C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, 2ND FLOOR, NEWTON MA 02459
Jatin Shah officer: EVP, Chief Medical Officer C/O KARYOPHARM THERAPEUTICS, INC., 85 WELLS AVENUE, NEWTON MA 02459
Sharon Shacham officer: C.S.O & Pres. of Res & Develop C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Michael Kauffman director, officer: President, C.E.O., C.M.O. C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Peter Honig director 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037